Your browser doesn't support javascript.
loading
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Hotz, Christian; Wagenaar, Timothy R; Gieseke, Friederike; Bangari, Dinesh S; Callahan, Michelle; Cao, Hui; Diekmann, Jan; Diken, Mustafa; Grunwitz, Christian; Hebert, Andy; Hsu, Karl; Bernardo, Marie; Karikó, Katalin; Kreiter, Sebastian; Kuhn, Andreas N; Levit, Mikhail; Malkova, Natalia; Masciari, Serena; Pollard, Jack; Qu, Hui; Ryan, Sue; Selmi, Abderaouf; Schlereth, Julia; Singh, Kuldeep; Sun, Fangxian; Tillmann, Bodo; Tolstykh, Tatiana; Weber, William; Wicke, Lena; Witzel, Sonja; Yu, Qunyan; Zhang, Yu-An; Zheng, Gang; Lager, Joanne; Nabel, Gary J; Sahin, Ugur; Wiederschain, Dmitri.
Affiliation
  • Hotz C; BioNTech, 55131 Mainz, Germany.
  • Wagenaar TR; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Gieseke F; BioNTech, 55131 Mainz, Germany.
  • Bangari DS; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Callahan M; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Cao H; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Diekmann J; BioNTech, 55131 Mainz, Germany.
  • Diken M; BioNTech, 55131 Mainz, Germany.
  • Grunwitz C; Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH (TRON), 55131 Mainz, Germany.
  • Hebert A; BioNTech, 55131 Mainz, Germany.
  • Hsu K; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Bernardo M; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Karikó K; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Kreiter S; BioNTech, 55131 Mainz, Germany.
  • Kuhn AN; BioNTech, 55131 Mainz, Germany.
  • Levit M; Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH (TRON), 55131 Mainz, Germany.
  • Malkova N; BioNTech, 55131 Mainz, Germany.
  • Masciari S; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Pollard J; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Qu H; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Ryan S; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Selmi A; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Schlereth J; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Singh K; Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH (TRON), 55131 Mainz, Germany.
  • Sun F; BioNTech, 55131 Mainz, Germany.
  • Tillmann B; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Tolstykh T; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Weber W; Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH (TRON), 55131 Mainz, Germany.
  • Wicke L; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Witzel S; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Yu Q; BioNTech, 55131 Mainz, Germany.
  • Zhang YA; Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH (TRON), 55131 Mainz, Germany.
  • Zheng G; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Lager J; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Nabel GJ; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Sahin U; Research and Development, Sanofi, Cambridge, MA 02139, USA.
  • Wiederschain D; Research and Development, Sanofi, Cambridge, MA 02139, USA.
Sci Transl Med ; 13(610): eabc7804, 2021 Sep 08.
Article in En | MEDLINE | ID: mdl-34516826
ABSTRACT
Local immunotherapy ideally stimulates immune responses against tumors while avoiding toxicities associated with systemic administration. Current strategies for tumor-targeted, gene-based delivery, however, are limited by adverse effects such as off-targeting or antivector immunity. We investigated the intratumoral administration of saline-formulated messenger (m)RNA encoding four cytokines that were identified as mediators of tumor regression across different tumor models interleukin-12 (IL-12) single chain, interferon-α (IFN-α), granulocyte-macrophage colony-stimulating factor, and IL-15 sushi. Effective antitumor activity of these cytokines relied on multiple immune cell populations and was accompanied by intratumoral IFN-γ induction, systemic antigen-specific T cell expansion, increased granzyme B+ T cell infiltration, and formation of immune memory. Antitumor activity extended beyond the treated lesions and inhibited growth of distant tumors and disseminated tumors. Combining the mRNAs with immunomodulatory antibodies enhanced antitumor responses in both injected and uninjected tumors, thus improving survival and tumor regression. Consequently, clinical testing of this cytokine-encoding mRNA mixture is now underway.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytokines / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytokines / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country:
...